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Abstract
Background: Chronic inflammation is considered to be implicated in the development of prostate cancer. In this
study we are the first to investigate a potential association between variants in an autoimmune related region on
chromosome 4q27 and prostate cancer risk. This region harbors two cytokine genes IL-2 and the recently
described IL-21.
Methods: We genotyped six variants previously associated with autoimmune disease (namely rs13151961,
rs13119723, rs17388568, rs3136534, rs6822844 and rs6840978) and one functional IL-2 promoter variant (rs2069762)
for possible association with prostate cancer risk using the Australian Risk Factors for Prostate Cancer case-control
Study.
Results: Overall, our results do not support an association between the seven variants at position 4q27 and
prostate cancer risk. Per allele odds ratios (ORs) were not significantly different from 1 (all P-values = 0.06).
However, we found suggestive evidence for a significant association between the presence of the rs13119723
variant (located in a protein of unknown function) and men with a family history of prostate cancer in first-degree
relatives (P-value for interaction 0.02). The per allele OR associated with this variant was significantly higher than 1
(2.37; 95% C.I. = 1.01-5.57).
Conclusions: We suggest that genetic variation within the chromosome 4q27 locus might be associated with
prostate cancer susceptibility in men with a family history of the disease. Furthermore, our study alludes to a
potential role of unknown protein KIAA1109 in conferring this risk.
Background
Prostate cancer is the most common cancer effecting
men in Western society and is the second highest con-
tributor to cancer-related deaths world-wide [1]. Despite
such vast prevalence little is known about the etiology
of prostate cancer. To date, there are three well-defined
risk factors, which include increased age, ethnicity and a
family history of the disease [2]; evidence for the latter
supporting a genetic contribution to prostate cancer
risk. More recently, inflammation has been implicated in
prostate cancer pathogenesis [3].
Different forms of prostate specific inflammation,
including chronic prostatitis and proliferative inflamma-
tory atrophy (PIA) have been frequently associated with
the development of prostate cancer [4,5]. As an under-
standing of the role of inflammation in the etiology of
prostate cancer begins to emerge, an imbalance in
cytokine production is thought to contribute to chronic
inflammation and a failed tumor immune response. Sug-
gestions that these specific inflammatory mediated con-
ditions may in fact be pre-cursor lesions to prostate
cancer development have prompted numerous investiga-
tions into identifying inflammatory gene variants that
might predispose individuals to prostate cancer risk.
(reviewed in [6]).
A 480 kilo base (kb) block of linkage disequilibrium
(LD) at chromosomal position 4q27 (Figure 1), harbors
two cytokine genes, Interleukin (IL)-2 and IL-21.T h e s e
genes encode proteins involved in numerous immune
f u n c t i o n ss u c ha st h ea c t i v a t i o na n dp r o l i f e r a t i o no f
immune cells including B-, T- and natural killer (NK)
cells. IL-2, which is produced primarily by activated
CD4+ effector T-cells, is a member of the common g-
chain cytokine family and appears to have pleiotropic
effects in the immune system, acting as both a pro- and
anti-inflammatory regulator [7]. Similarly, IL-2 has been
described as contributing to both pro- and anti-tumor
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noma, administration of a high dose IL-2 based immu-
notherapy correlates with an elevated T regulatory
(Treg) cell response associated with down regulation of
tumor specific immunity [8]. Alternatively lower doses
of IL-2 for treatment of common malignancies including
prostate cancer contributes to an anti-tumor immune
response via activation of tumor specific NK cells
[9-11]. A balanced IL-2 cytokine production in the pros-
tate microenvironment may thus contribute to prostate
cancer susceptibility. To date, a single prostate cancer
association study has investigated genetic variants within
IL-2 for prostate cancer risk and revealed a significant
contribution of a synonymous IL-2 exon 1 variant
(rs2069763) to disease susceptibility [12].
IL-21 is the most recently described member of the
common g-chain cytokine family. Similarly to IL-2, IL-
21 is expressed by activated CD4+ T-cells and has been
described as having anti-tumor effects in mouse models
for several different malignancies, including prostate
cancer [13]. Experimental models have demonstrated
the anti-tumor potential of IL-21, via expansion of
tumor specific CD8+ effector T cells and suppression of
anti-inflammatory Treg cells [14]. IL-21 is involved in
T-helper type 17 (Th17) effector cell function [15],
which has been implicated in prostate cancer develop-
ment [16] and more recently with progression to metas-
tasis [17]. No studies have to date investigated the
potential role of IL21 variation in prostate cancer
susceptibility.
In addition to IL-2 and IL-21, the 480 kb region at
4q27 encompasses genes encoding testis nuclear RNA-
binding protein (TENR) and a protein of unknown func-
tion, KIAA1109. The chromosomal region at position
4q27 has been highlighted as a potential risk locus in
genome-wide association studies (GWAS) and candidate
gene studies for several common inflammatory disorders
including celiac disease, type 1 diabetes, rheumatoid
arthritis, systemic lupus erythematosus (SLE), psoriasis,
multiple sclerosis and both forms of inflammatory
bowel disease (IBD), ulcerative colitis and Chron’sd i s -
ease [18-24]. Although replication studies have con-
firmed 4q27 as a risk locus for inflammatory disorders
[22,24-29], tight linkage disequilibrium (LD), essentially
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Figure 1 Pairwise LD for gene variants located within approximately 480 kb at chromosomal position 4q27. The 4q27 region harbors
cytokine coding genes IL-2 and IL-21, testis nuclear RNA-binding protein coding gene TENR and a gene coding for a protein of unknown
function, KIAA1109. The seven selected SNPs (indicated by rs numbers) in this study display tight linkage across the region. The reference
genome assembly used to determine physical SNP position was NCBI Build version 36.3.
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prostate cancer risk locus, in turn limits identification of
the true casual variant.
The proposed link between the 4q27 locus and auto-
immune disease susceptibility is suggestive of a func-
tional role for this region in maintaining a balanced
immune response. Under the proposed hypothesis that
chronic inflammation may mediate prostate cancer
development, further supported by casual observations
of tentative association between the incidence of pros-
tate cancer and several common immune disorders
including ulcerative colitis [30], rheumatoid arthritis
[31], Crohn disease [32] and asthma [33], we investigate
a potential role for the 4q27 region in prostate cancer
susceptibility. Six autoimmune associated variants and a
single functional variant were genotyped using a large
Australian-based case-control study of prostate cancer.
Methods
Study Population
The Risk Factors for Prostate Cancer (RFPC) study is a
population-based case-control study of 825 cases and
734 controls from the Melbourne and Perth metropoli-
tan areas of Australia, and defined in Additional file 1.
The men of predominantly European descent (including
9 cases and 13 controls of Asian origin) were recruited
between 1994 and 1998 and described in detail else-
where [34]. Eligible cases were diagnosed with histo-
pathologically confirmed prostate cancer via the State
Cancer Registries and included irrespective of familial
status. Cases were diagnosed before age 70 years with a
Gleason Score >4. Tumor stage (stage I to IV) and
grade (moderate: Gleason 5-7; high: Gleason 8-10) were
obtained from histopathological reports. Controls were
randomly selected from the State Electoral Rolls and fre-
quency matched to the expected age distribution of
cases. Information including age, family history of pros-
tate cancer (in first-degree relatives), country of birth,
and lifestyle were recorded during a face-to-face inter-
view. Ethics approval for this study was obtained from
The Cancer Council Victoria Human Research Ethics
Committee, Australia (HREC0808).
Variant Selection and Genotyping
Seven single nucleotide variants across the 4q27 locus
were selected for analysis with prostate cancer risk. Six
(rs13151961, rs13119723, rs17388568, rs3136534,
rs6822844 and rs6840978) were chosen due to highly
significant associations reported in previous studies for
autoimmune disease susceptibility. These associations
may reflect an as yet unknown biological effect of these
variants. The IL-2 promoter variant (rs2069762) was
specifically selected based on previous functional reports
[35,36].
The six variants rs13151961, rs13119723, rs17388568,
rs3136534, rs6822844 and rs6840978 were genotyped
using Applied Biosystem 7900HT TaqMan allelic discri-
mination method, with an average 11.5% random study
replication. The IL-2 promoter variant rs2069762, was
genotyped on two platforms using the Sequenom Mas-
sArray using homogenous MassExtend (hME) and Taq-
Man allelic discrimination methods. Study replication
was performed for the purpose of platform and chemis-
try assessment and quantification, as previously pub-
lished [37].
Statistical Analysis
Allele frequency estimates and tests of deviation from
Hardy-Weinberg equilibrium (HWE) were carried out
using standard procedures based on asymptotic likeli-
hood theory [38]. Unconditional logistic regression analy-
sis was used to test for independence between the
variants and age (<55, 55-59, >60), country of birth (Aus-
tralia, others) and family history of prostate cancer
(affected first-degree relative and two or more first
degree relatives affected). Case-control analyses were
conducted using unconditional logistic regression and
OR estimates and their 95% confidence intervals (CI)
were derived under likelihood theory. We fitted domi-
nant, recessive, co-dominant, and per allele models. Het-
erogeneity in the odds ratios by age and family history of
prostate cancer in first-degree relatives (0 or at least one)
was tested by including an interaction term in the logistic
model. One polytomous logistic regression model was
used to estimate odds ratios (OR) for stage I-II and stage
III-IV tumors and another to estimate ORs for moderate-
grade and high-grade tumors. In order to test for hetero-
geneity in the ORs by tumor stage or grade, the likeli-
hood from these models was compared with that from
polytomous logistic regression models with ORs con-
strained not to vary by tumour stage or grade. All statisti-
cal analyses were performed using Stata 10 (Stata
Corporation). All tests were two-sided and a 5% level was
used as the threshold for statistical significance.
Results
Genotype calls were achieved for more than 99% of the
study samples, with a 100% genotyping replication con-
cordance using TaqMan allelic discrimination. Genotype
distributions were consistent with HWE for cases and
controls as well as cases and controls combined (all P >
0.19). No significant association was observed between
genotypes and tumor stage or grade, age of prostate
cancer diagnosis, prostate-specific antigen (PSA) levels,
or country of birth for any of the variants we assessed
in this study.
Overall we found no significant association between
the seven variants and prostate cancer risk (Additional
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0.79-1.07) to 1.16 (95% C.I. = 1.00-1.35) and they were
all not significantly different from 1 (P = 0.06). The ORs
were virtually unchanged after excluding the 22 men
that were born in Asia. For rs3136534, the dominant
model showed marginal evidence of association with
risk: the OR for carriers of the rare allele versus carriers
of two copies of the common allele was 1.23 (95% C.I. =
1.00-1.50, P-value = 0.046). Analysis by tumor stage,
grade and age did not show any significant association.
Analysis by family history of prostate cancer (Additional
file 3) however showed evidence that the G allele for the
intronic KIAA1109 variant rs13119723, was significantly
more frequent in men with a family history compared
to those with no family history (P-value for interaction
= 0.02). The per allele OR associated with this variant
was significantly higher than 1 (2.37; 95% C.I. = 1.01-
5.57) for men with a family history of prostate cancer.
Previous studies have reported a strong degree of LD
within the 4q27 gene locus. Our results similarly support
a high degree of linkage within this region (Figure 1).
Discussion
Results using the RFPCS suggest that genetic variation
at chromosomal region 4q27 is not associated with over-
all prostate cancer risk. At 0.05 level of significance
under a dominant model the sample size of our study
allows to detect with 80% power a minimum OR of 1.33
for the most common SNP (rs2069762) and 1.36 for the
least common SNP (rs13151961). The corresponding
minimum detectable ORs under a recessive model are
1.54 and 2.11. Analysis of men with a family history of
the disease, however, indicates that this region may be a
risk locus for familial prostate cancer.
The potential role of chronic inflammation in prostate
cancer development, together with an observed association
between the 4q27 region and susceptibility to autoimmune
disease and in turn immune dysfunction, implicates the
cytokine rich 4q27 region as a candidate prostate cancer
risk locus. IL-2 and IL-21 are involved in regulating an
immune response at multiple intervals, thus genetic varia-
tion likely to influence the function of these cytokines may
have catastrophic effects to host immunity.
Although IL-2 is well studied for association with
autoimmune diseases, only a single study has investi-
gated genetic association with risk for prostate cancer,
implicating an indirect prostate cancer susceptibility
marker [12], with no direct functional significance [39].
In our study we elected to screen the promoter variant
rs2069762, shown to influence IL-2 production up to 3-
fold [35,36] for a possible direct association. Although
our results show no significant association for
rs2069762, this is the first study to address the potential
role of this variant in prostate cancer risk. The variant
rs3136534 in the IL2 3’ untranslated region (UTR) how-
ever, displayed a marginally significant association with
risk for prostate cancer.
The IL-21 gene is still considered a relatively newly
discovered cytokine, and thus few disease association
studies have been reported. Candidate gene studies have
identified single variants (not observed on GWAS)
within IL-21 to be associated with autoimmune diseases
including SLE [40], type 1 diabetes [41] and atopic
asthma [42]. The latter study identified a synonymous
exon 3 variant (rs4833837), also reported to correlate
with serum levels of immunoglobulin (Ig)E and IL-21
[42]. These results further implicate IL-21 in maintain-
ing and regulating an immune response, although a high
degree of LD within this gene region has hindered
efforts to narrow the locus to its true causal variants.
Despite suggestions that rs4833837 is associated with
differential IL-21 activity, as yet no direct functional role
for any IL-21 variant has been reported. In this study we
selected variants that were most significantly associated
with autoimmune disease susceptibility and are the first,
to our knowledge to investigate variants within the
IL-21 gene region for prostate cancer risk.
A family history of prostate cancer has long been
accepted as a major contributor to an increased risk of
developing the disease [2]. Identification of variants
responsible for this inherent risk can be achieved by asses-
sing variant frequency in cases with affected relatives. For
the KIAA1109 rs13119723 variant, we found an increased
OR for men with a family history of prostate cancer. This
result reflects a different genotype distribution for both
cases and controls with a family history compared with
cases and controls with no family history. However, we
cannot exclude the possibility that the increased OR may
be due to chance and to the relatively small number of
men with a family history of prostate cancer in our study.
Although prostate cancer GWAS have thus far failed
to implicate the 4q27 region as a candidate risk locus,
the growing number of candidate gene regions already
identified in these large-scale studies, highlights the
complex and heterogeneous nature of prostate cancer.
Thus, multiple, low to moderate risk alleles (not yet
identified by GWAS) may still be implemented in the
disease. It could therefore be argued that our pathway-
linked gene approach to identify modest risk loci, in
combination with large scale GWAS, may be appropri-
a t et oe n s u r ec o m p l e t ec o v e r a g eo fp o t e n t i a lp r o s t a t e
cancer risk factors.
Conclusions
To establish whether the 4q27 cytokine rich region is a
locus for familial prostate cancer risk as suggested in this
study, the association needs to be replicated in indepen-
dent studies that include a larger number of men with a
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gene of as yet unknown function, few functionally relevant
variants within this region have been elucidated. Hence, a
more comprehensive analysis of potentially functional var-
iants within 4q27 may provide a more accurate approach
for analysis of prostate cancer susceptibility.
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